Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Stimulation transcutanée du nerf tibial dans les lésions aiguës de la moelle épinière (TASCI)

2 novembre 2026 mis à jour par: University of Zurich

Stimulation transcutanée du nerf tibial chez les patients présentant une lésion médullaire aiguë pour prévenir l'hyperactivité neurogène du détrusor : un essai clinique national randomisé, contrôlé par simulation, en double aveugle

Most patients with spinal cord injury (SCI) develop neurogenic lower urinary tract dysfunction (NLUTD), one of the most devastating sequelae of SCI which ultimately can lead to renal failure. We urgently need an intervention that prevents NLUTD before irreversible damage occurs. Neuromodulation procedures are a promising avenue so that we investigate the effect of transcutaneous tibial nerve stimulation (TTNS) in patients with acute SCI.

This nationwide randomized, sham-controlled, double-blind multicentre clinical trial includes all SCI centres in Switzerland (Basel, Nottwil, Sion, Zürich). Patients are randomly assigned to VERUM TTNS (active stimulation, n=57) and SHAM stimulation (n=57) groups in a 1:1 allocation using computer-generated permuted block randomisation lists stratified on study centre and lower extremity motor score. Daily 30-minute sessions are performed five times a week during an intervention period of 6-9 weeks. The primary outcome of this study is the success of TTNS to prevent neurogenic DO jeopardizing the upper urinary tract, assessed by urodynamics at 1 year after SCI or any earlier time point if DO treatment is necessary (study end). Secondary outcome measures are bladder diary parameters, clinical symptom scores assessed by standardized and validated questionnaires. Furthermore, neurophysiological and neuroimaging outcome measures are assessed as well as, biochemical and molecular changes. Tertiary outcome measure is the safety of TTNS.

Before the actual start of the TASCI RCT, start-up activities will include a piloting phase on groups of healthy volunteers and patients. The goal during this phase is to evaluate the feasibility of the experimental setup, in particular for the TTNS and SHAM intervention, but also to test the setup of the different pre and post assessments (e.g. neurophysiology and neuroimaging tests). Groups of up to 15 participants each will be enrolled in a few consecutive pilot studies allowing for fine tuning and small adaptations in between, if appropriate.

Aperçu de l'étude

Statut

Recrutement

Type d'étude

Interventionnel

Inscription (Estimé)

114

Phase

  • N'est pas applicable

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Coordonnées de l'étude

Sauvegarde des contacts de l'étude

Lieux d'étude

      • Basel, Suisse
        • Recrutement
        • REHAB Basel
        • Contact:
        • Chercheur principal:
          • Sandra Möhr, pract. med.
      • Nottwil, Suisse
        • Recrutement
        • Swiss Paraplegic Centre
        • Contact:
        • Chercheur principal:
          • Jürgen Pannek, Prof. Dr. med.
      • Sion, Suisse
        • Recrutement
        • Spinal Cord Injury Department, Clinique romande de réadaption
        • Contact:
        • Chercheur principal:
          • Xavier Jordan, Dr. med.
    • Canton of Zurich
      • Zurich, Canton of Zurich, Suisse, 8008
        • Recrutement
        • Department of Neuro-Urology, Spinal Cord Injury Centre & Research, Balgrist University Hospital
        • Contact:
        • Chercheur principal:
          • Thomas M Kessler, Prof. Dr. med.

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

18 ans et plus (Adulte, Adulte plus âgé)

Accepte les volontaires sains

Non

Sexes éligibles pour l'étude

Tout

La description

Inclusion Criteria:

  • Age >18 years

  • Patients with acute SCI (traumatic SCI and sudden onset (<7 days) non-traumatic SCI) within 40 days after injury

  • Patients with acute SCI at cervical or thoracic level

  • Willing to take part and follow the requirements of the TASCI protocol (up to one year after SCI)

    • no percutaneous tibial nerve stimulation (PTNS)
    • no functional electrical stimulation (FES), apart from upper limb FES
    • no electrical muscle stimulation (EMS)
  • Informed Consent

Exclusion Criteria:

  • Contraindications to the investigational product
  • DO with contractions greater than 40 cmH2O at a bladder filling volume of less than 500mL at baseline visit
  • Treatment with antimuscarinics or with mirabegron
  • Known or suspected non-adherence, drug or alcohol abuse
  • Inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, dementia, etc. of the participant
  • Participation in another study with investigational drug or product within the 30 days preceding and during the present study
  • Neuromodulation treatment for urological or bowel indication in the last six months or ongoing
  • Botulinum toxin injections in the detrusor and/or urethral sphincter in the last six months
  • Bilaterally absent tibial nerve compound muscle action potential (cMAP, amplitude < 1mV)
  • Women who are pregnant or breast feeding
  • Intention to become pregnant during the course of the study
  • Individuals especially in need of protection (according to Research with Human Subjects published by the Swiss Academy of Medical Sciences [www.samw.ch/en/News/News.html])
  • Enrolment of the investigator, his/her family members, employees and other dependent persons
  • Pre-existing or concomitant medical condition apart from SCI that might pose a safety issue or would interfere with interpretation of study results or study conduct (e.g. Parkinson's disease, neurodegenerative disorders including multiple sclerosis and amyotrophic lateral sclerosis, urological malignancies)

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: La prévention
  • Répartition: Randomisé
  • Modèle interventionnel: Affectation parallèle
  • Masquage: Tripler

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Expérimental: Stimulation transcutanée du nerf tibial VERUM (TTNS)
  • Daily 30-minute TTNS intervention is performed 5 days a week during a treatment period of 6-9 weeks, until 3-month post assessments
  • During a preparation phase of several minutes, sensory and motor thresholds are assessed and stimulation intensities are adjusted for the following 30-minute treatment phase
Comparateur factice: SHAM stimulation transcutanée du nerf tibial (TTNS)
  • Daily 30-minute SHAM intervention is performed 5 days a week during a treatment period of 6-9 weeks, until 3-month post assessments
  • During a preparation phase of several minutes, sensory and motor thresholds are assessed and stimulation intensities are adjusted for the following 30-minute treatment phase

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
The occurrence of neurogenic DO jeopardizing the upper urinary tract
Délai: up to 12 months after SCI

Defined as composite measure: Urodynamic assessment establishing DO amplitude ≥40 cmH2O; or else initiation of DO treatment (with antimuscarinics and/or intradetrusor onabotulinumtoxinA injections)

up to 12 months after SCI

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Modifications de la compliance vésicale [mL/cmH2O] au cours de l'urodynamique et leur relation avec les résultats cliniques
Délai: Base de référence ; 3 mois après une lésion médullaire ; 6 mois après une lésion médullaire ; 12 mois après SCI / fin d'étude
Base de référence ; 3 mois après une lésion médullaire ; 6 mois après une lésion médullaire ; 12 mois après SCI / fin d'étude
Modifications du débit maximal [mL/s] telles qu'évaluées par l'urodynamique et leur relation avec les résultats cliniques
Délai: Base de référence ; 3 mois après une lésion médullaire ; 6 mois après une lésion médullaire ; 12 mois après SCI / fin d'étude
Base de référence ; 3 mois après une lésion médullaire ; 6 mois après une lésion médullaire ; 12 mois après SCI / fin d'étude
Modifications du reflux vésico-urétéro-rénal (RVU) évaluées par vidéographie au cours de l'urodynamique et leur relation avec les résultats cliniques
Délai: Base de référence ; 3 mois après une lésion médullaire ; 6 mois après une lésion médullaire ; 12 mois après SCI / fin d'étude
Base de référence ; 3 mois après une lésion médullaire ; 6 mois après une lésion médullaire ; 12 mois après SCI / fin d'étude
Modifications de l'activité du plancher pelvien évaluées par électromyographie (EMG) au cours de l'urodynamique et leur relation avec les résultats cliniques
Délai: Base de référence ; 3 mois après une lésion médullaire ; 6 mois après une lésion médullaire ; 12 mois après SCI / fin d'étude
Base de référence ; 3 mois après une lésion médullaire ; 6 mois après une lésion médullaire ; 12 mois après SCI / fin d'étude
Changements dans les ensembles de données sur la fonction sexuelle féminine / masculine de l'International Spinal Cord Society (ISCoS) et leur relation avec les résultats cliniques
Délai: Base de référence ; 3 mois après une lésion médullaire ; 6 mois après une lésion médullaire ; 12 mois après SCI / fin d'étude
Base de référence ; 3 mois après une lésion médullaire ; 6 mois après une lésion médullaire ; 12 mois après SCI / fin d'étude
Modifications de la compliance rectale [mL/cmH2O] pendant l'évaluation de la manométrie anorectale et du barostat et leur relation avec les résultats cliniques
Délai: Base de référence ; 3 mois après une lésion médullaire ; 6 mois après une lésion médullaire ; 12 mois après SCI / fin d'étude
Base de référence ; 3 mois après une lésion médullaire ; 6 mois après une lésion médullaire ; 12 mois après SCI / fin d'étude
Modifications des mesures neurophysiologiques des potentiels évoqués (PE) ainsi que des mesures de conduction nerveuse et leur relation avec les résultats cliniques
Délai: Base de référence ; 3 mois après une lésion médullaire ; 6 mois après une lésion médullaire ; 12 mois après SCI / fin d'étude
Base de référence ; 3 mois après une lésion médullaire ; 6 mois après une lésion médullaire ; 12 mois après SCI / fin d'étude
Modifications de la neurophysiologie des voies urinaires inférieures (LUT) : seuils de perception actuels (CPT) et potentiels évoqués sensoriels LUT (LUTSEP) avec leur relation avec les résultats cliniques
Délai: Base de référence ; 3 mois après une lésion médullaire ; 6 mois après une lésion médullaire ; 12 mois après SCI / fin d'étude
Base de référence ; 3 mois après une lésion médullaire ; 6 mois après une lésion médullaire ; 12 mois après SCI / fin d'étude
Modifications des marqueurs inflammatoires dans le tissu vésical, le sang et l'urine, ainsi que leur relation avec les résultats cliniques
Délai: Base de référence ; 3 mois après une lésion médullaire ; 6 mois après une lésion médullaire ; 12 mois après SCI / fin d'étude
Base de référence ; 3 mois après une lésion médullaire ; 6 mois après une lésion médullaire ; 12 mois après SCI / fin d'étude
Modifications du tissu vésical et leur relation avec les résultats cliniques
Délai: Base de référence ; 3 mois après une lésion médullaire ; 6 mois après une lésion médullaire ; 12 mois après SCI / fin d'étude
Base de référence ; 3 mois après une lésion médullaire ; 6 mois après une lésion médullaire ; 12 mois après SCI / fin d'étude
Volumetric changes during urodynamics and their relation to clinical outcomes
Délai: Baseline; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end

Cystometric capacity [mL], volume at first DO [mL], voided volume [mL] and post void residual [mL] as assessed by urodynamic measurement

Baseline; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end
Pressure changes during urodynamics and their relation to clinical outcomes
Délai: Baseline; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end

Maximum DO amplitude [cmH2O], detrusor leak-point pressure [cmH2O], maximum detrusor pressure [cmH2O] during storage phase, maximum detrusor pressure [cmH2O] during voiding phase, detrusor pressure at maximum flow rate [cmH2O] as assessed by urodynamic measurement

Baseline; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end
Changes in bladder storage and voiding parameters and their relation to clinical outcomes
Délai: Baseline; once every 2 weeks during the TTNS intervention period; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end

Assessed by a bladder diary

Baseline; once every 2 weeks during the TTNS intervention period; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end
Changes in bowel diary parameters and their relation to clinical outcomes
Délai: Baseline; once every 2 weeks during the TTNS intervention period; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end

Assessed by a bowel diary

Baseline; once every 2 weeks during the TTNS intervention period; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end
Changes in International Prostate Symptom (IPSS) questionnaire and their relation to clinical outcomes
Délai: Baseline; once per week during the TTNS intervention period; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end

The IPSS ("International Prostate Symptom Questionnaire") score is based on questions concerning urinary symptoms and quality of life (QoL). It consists of 8 items covering 7 urinary symptoms related dimensions (subscales) and 1 additional item assessing quality of life. Each item is rated on a 6-point scale (0=not at all; 5=almost always). The lowest possible score in the total IPSS score is 0 (asymptomatic); the highest possible score is 35 (symptomatic). The QoL index is rated on a 7-point scale, with 0 indicating "delighted" and 6 "terrible."

Baseline; once per week during the TTNS intervention period; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end
Changes in urinary symptoms as assessed by the Urinary Symptom Profile (USP) questionnaire and their relation to clinical outcomes
Délai: Baseline; once per week during the TTNS intervention period; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end

The USP ("Urinary Symptom Profile") score is based on questions concerning urinary symptoms and their severity in males and females. It consists of 13 items covering 3 dimensions (subscales) with 7 overactive bladder (OAB), 3 stress urinary incontinence (SUI), and 3 low stream (LS) related items. Each item is rated on a 4-point scale. The lowest score is 0 (asymptomatic); the highest score is 3 (symptomatic).

Baseline; once per week during the TTNS intervention period; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end
Changes in Qualiveen questionnaire scores and their relation to clinical outcomes
Délai: Baseline; once per week during the TTNS intervention period; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end

Qualiveen-30 assesses the Specific Impact of Urinary Problems (SIUP) on Quality of Life. It consists of 30 items covering 4 domains, namely inconvenience (9 questions), restrictions (8 questions), fears (8 questions), and impact on daily life (5 questions). Each item is rated on a 5-point ordinal scale (0=asymptomatic; 4=symptomatic). The index of the SIUP on Quality of Life is the mean of the four individual scores. The lowest possible overall score in the Qualiveen-30 is 0 (Urinary problems have no specific impact on QoL); the highest possible score is 30 (Urinary problems have a huge specific impact on QoL).

Baseline; once per week during the TTNS intervention period; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end
Changes in Female Sexual Function Index (FSFI) and their relation to clinical outcomes
Délai: Baseline; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end

The FSFI ("Female Sexual Function Index") is based on questions concerning female sexual functions. It consists of 19 items covering 6 domains, namely sexual desire, arousal (both subjective and physiologic), lubrication, orgasm, satisfaction, and pain. The lowest possible score in the total FSFI is 2 (asymptomatic); the highest possible score is 36 (symptomatic).

Baseline; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end
Changes in International Index of Erectile Function (IIEF) and their relation to clinical outcomes
Délai: Baseline; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end

The IIEF ("International Index of Erectile Function") is based on questions concerning erectile dysfunction. It consists of 15 items covering 5 domains, namely erectile functioning, orgasmic functioning, sexual desire, and intercourse satisfaction along with a fifth component which encompasses the concept of overall sexual satisfaction. While items 1-10 are rated on a 6-point Likert-type scale from 0 to 5, items 11-15 are rated on a 5-point Likert-type scale from 1 to 5. Higher scores are reflecting less dysfunction. Domain scores are computed by summing the sores for individual items in each domain.

Baseline; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end
Changes in Neurogenic Bowel Dysfunction (NBD) score and their relation to clinical outcomes
Délai: Baseline; once per week during the TTNS intervention period; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end

The NBD ("Neurogenic Bowel Dysfunction") score is based on questions concerning constipation and fecal incontinence and was developed for and validated in the spinal cord injury population. It consists of 10 items. The lowest possible score in the total NBD is 0 (asymptomatic); the highest possible score is 47 (symptomatic). The interpretation of the total NBD score is very minor NBD (0-6), minor NBD (7-9), moderate NBD (10-13), and severe NBD (≥14).The NBD score is assessed by using the international spinal cord injury (ISCoS) bowel function basic data set.

Baseline; once per week during the TTNS intervention period; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end
Volumetric changes during rectal sensitivity testing and barostat assessment and their relation to clinical outcomes
Délai: Baseline; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end

Initial sensation [mL], volume at urge to defecate [mL], maximum tolerated volume [mL] as assessed by rectal sensitivity testing; rectal capacity [mL] assessed by barostat assessment

Baseline; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end
Pressure changes during anorectal manometry and barostat assessment and their relation to clinical outcomes
Délai: Baseline; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end

Basal internal anal sphincter pressure [mmHg], squeeze external anal sphincter pressure [mmHg], relaxation internal anal sphincter pressure during defecation [%, mmHg], intraabdominal pressure during defecation [mmHg]

Baseline; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end
Changes in defecatory disorder [Rao's classification] identified during anorectal manometry and their relation to clinical outcomes
Délai: Baseline; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end

Anorectal manometry is the preferable test for defecatory disorder. Rao's classification describes the four types of manometric patterns (I-IV) that are identified through manometric assessments

Baseline; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end
Changes International Standards for Neurological Classification of Spinal Cord Injury (ISNCSCI) protocol
Délai: Baseline; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end

International Standards for Neurological Classification of Spinal Cord Injury (ISNCSCI) assessment to quantify the severity of the spinal cord injury

Baseline; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end
Changes in Lower Extremities Motor Scale (LEMS) from International Standards for Neurological Classification of Spinal Cord Injury (ISNCSCI) protocol
Délai: Baseline; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end

LEMS is based on assessments of ISNCSCI and composed from the sum of muscle function grading of the five key muscles of the lower limbs. It consists of a 6-point scale (0=no; 5=normal activity) for each muscle and body site. The lowest possible score in the total LEMS score for one body site is 0 (symptomatic); the highest possible score is 50 (asymptomatic).

Baseline; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end
Changes in Upper Extremities Motor Scale (UEMS) from International Standards for Neurological Classification of Spinal Cord Injury (ISNCSCI) protocol
Délai: Baseline; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end

UEMS is based on assessments of ISNCSCI and composed from the sum of muscle function grading of the five key muscles of the upper limbs. It consists of a 6-point scale (0=no; 5=normal activity) for each muscle and body site. The lowest possible score in the total LEMS score for one body site is 0 (symptomatic); the highest possible score is 50 (asymptomatic).

Baseline; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end
Changes in Spinal Cord Independence Measure III (SCIM-III) and their relation to clinical outcomes
Délai: Baseline; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end

The SCIM-III ("Spinal Cord Independence Measure III") score is based on questions concerning independence of persons with a spinal cord injured. It consists of 19 items covering 3 domains, self-care, respiration and sphincter management, and mobility. The self-care subscale ranges from 0 to 20. The respiration and sphincter management subscale ranges from 0 to 40. The mobility subscale ranges from 0 to 40. Total score ranges from 0 (symptomatic) to 100 (asymptomatic). Higher scores reflect higher levels of independence.

Baseline; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end
Changes in spasticity in the knee and elbow flexors and extensors from the Modified Ashworth Scale (MAS) assessment and their relation to clinical outcomes
Délai: Baseline; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end

The MAS is a 5-point nominal scale that uses subjective clinical assessments of muscle tone ranging from 0 - 'No increases in tone' to 4 - 'Limb rigid in flexion or extension'. A grade of (1+) indicates resistance in the movement.

Baseline; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end
Changes in spasticity in daily life as assessed by the Spinal Cord Injury Spasticity Evaluation Tool (SCI-SET) questionnaire and their relation to clinical outcomes
Délai: Baseline; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end

The SCI-SET ("Spinal Cord Injury Spasticity Evaluation Tool ") score is based on questions concerning the positive and negative effects of spasticity on different areas of daily life. Each of the 35 items are rated on a 7-point scale (-3=extremely problematic; 0=no effect; 3=extremely helpful). Calculations include counts and sum scores of areas of daily life where spasticity is problematic (count range: 0 to 35, sum score range: 35 to 0) or helpful (counts range: 0 to 35, sum score range: 0 to +35) as well as a mean score of all applicable items (range: -3 to +3)

Baseline; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end
Changes in frequency power of surface electromyography (EMG) and electroencephalography (EEG) and their relation to clinical outcomes
Délai: Baseline; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end

Fast Fourier Transformation analysis for delta, theta, alpha, beta, and gamma band power as assessed via EEG of the cortex and EMG of the muscle

Baseline; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end
Changes in EMG and EEG coherence measures and their relation to clinical outcomes
Délai: Baseline; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end

Coherence for EEG and EMG signals computed as cortico-muscular, inter- and intra-muscular coherence for typical EEG/EMG frequency bands (delta, theta, alpha, beta, and gamma).

Baseline; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end
Changes in white and gray matter area in the lumbosacral enlargement (LSE) and their relation to clinical outcomes
Délai: Baseline; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end

White and gray matter areas are obtained by segmenting the T2*-weighted MRI images for white and gray matter at the level of LSE

Baseline; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end
Changes in white and gray matter area in upper cervical cord (at C2/C3) and their relation to clinical outcomes
Délai: Baseline; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end

Obtained by segmenting the T2*-weighted MRI images for white and gray matter at the vertebral level C2/C3.

Baseline; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end
Changes in white and gray matter volume of the conus medullaris (CM) and their relation to clinical outcomes
Délai: Baseline; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end

White and gray matter volume are obtained by segmenting the T2*-weighted MRI images for white and gray matter in the CM

Baseline; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end
Changes in gray and white matter volume in the brain and their relation to clinical outcomes
Délai: Baseline; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end

Gray and white matter volume in the brain are computed by feeding the whole-brain T1-weighted MRI images into a voxel-based morphometry algorithm. Changes in the gray and white matter volume will be evaluated in urologically relevant brain areas.

Baseline; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end
Changes in fractional anisotropy (FA) in the brain and spinal cord and their relation to clinical outcomes
Délai: Baseline; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end

FA is a common dimensionless measure used in Diffusion Tensor Imaging (DTI) studies and ranges from 0, isotropic movement of water molecules (e.g., cerebrospinal fluid), to 1, fully anisotropic movement of water molecules (e.g., fiber bundles).

Baseline; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end
Changes in diffusivity in the brain and spinal cord and their relation to clinical outcomes
Délai: Baseline; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end

Mean, axial, and radial diffusivity (MD, AD, RD) are common measures used in DTI studies providing information about the integrity of the underlying tissue.

Baseline; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end
Changes in brain and spinal cord tissue microstructure and their relation to clinical outcomes
Délai: Baseline; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end

Quantitative tissue parameters assessed using MRI Multi-Parameter Mapping.

Baseline; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end
Expression profile of microRNA (miRNA) in urine and blood as well as their relation to clinical outcomes
Délai: Baseline; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end

MicroRNA (miRNA) sequencing is used to identify regulated miRNAs specific to TTNS intervention in urine and blood.

Baseline; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end
Changes in levels of neurotransmitters (neurotrophins) in blood, and urine, as well as their relation to clinical outcomes
Délai: Baseline; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end

Analysis will be performed using ELISA to detect molecules likely to be involved in the underlying molecular mechanisms of neuromodulation.

Baseline; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end
Changes in the composition of urinary and stool microbiome and their relation to clinical outcomes
Délai: Baseline; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end

Gut and bladder microbial patterns are determined from stool and urine samples

Baseline; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end

Autres mesures de résultats

Mesure des résultats
Description de la mesure
Délai
Incidence of side effects as well as number and intensity/severity (mild/moderate/severe) of adverse events (AEs) and serious adverse events (SAEs) for the following categories:
Délai: During complete study period, up to 12 months
  • infection - Urinary Tract Infection (UTI)
  • infection - other than UTI
  • skin irritation at the electrode site
  • irritation-related symptoms (e.g. dysuria, hematuria) immediately following a LUT intervention
  • neuro-urological deterioration
  • pressure ulcer
  • neurological deterioration
  • increase in pain
  • increase in spasticity
  • deep vein thrombosis / pulmonary embolism
  • autonomic dysreflexia
  • transfer/admittance to an acute care facility
During complete study period, up to 12 months

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Les enquêteurs

  • Chaise d'étude: Thomas M. Kessler, Prof. Dr. med., University of Zurich
  • Chercheur principal: Thomas M. Kessler, Prof. Dr. med., Balgrist University Hospital
  • Chercheur principal: Armin Curt, Prof. Dr. med., Balgrist University Hospital
  • Chercheur principal: Jürgen Pannek, Prof. Dr. med., Swiss Paraplegic Centre
  • Chercheur principal: Martin Brinkhof, Dr., Swiss Paraplegic Research, Nottwil

Publications et liens utiles

La personne responsable de la saisie des informations sur l'étude fournit volontairement ces publications. Il peut s'agir de tout ce qui concerne l'étude.

Publications générales

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Réel)

19 juin 2019

Achèvement primaire (Estimé)

30 septembre 2028

Achèvement de l'étude (Estimé)

30 septembre 2028

Dates d'inscription aux études

Première soumission

26 mars 2019

Première soumission répondant aux critères de contrôle qualité

23 mai 2019

Première publication (Réel)

29 mai 2019

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

5 novembre 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

2 novembre 2026

Dernière vérification

1 novembre 2026

Plus d'information

Termes liés à cette étude

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

OUI

Description du régime IPD

All individual participant data (IPD) and data dictionaries that underlie results in a publication are to be uploaded to a public data registry in cases where this can be done without compromising patient privacy. Given the small size of the dataset and that spinal cord injury (SCI) is a rare condition, to ensure identity protection any publicly available dataset(s) will be modified to reduce the number of indirect identifier variables, e.g. continuous variables such as age will be grouped, categorical or binary variables with small group numbers such as study centre will not be provided. When data sets cannot be sufficiently de-identified to be made publicly available, they will be made available upon reasonable request. Data judged to be confidential to participants or the participating study centers will not be released, but efforts will be made to provide scientifically meaningful equivalent information.

Délai de partage IPD

Post-publication data packages, containing the analysis data set presented in scientific reports will be available starting 6 months after the publication date. Data that are not being prepared for publication will be available to secondary users starting 4 years after study completion or discontinuation. All data will be kept for at least 10 years after study completion or discontinuation.

Critères d'accès au partage IPD

Requests for data access will be reviewed by the TASCI steering committee, which includes the four project PIs and representatives from each of the participating study centers. The steering committee will request a project plan, including at a minimum an abstract and a list of author names and roles, from the leaders of all projects wishing to use TASCI study data. Project plans will be evaluated on the basis of scientific validity, and also on whether they include adequate measures to protect patient privacy. Secondary users will be asked to sign a data use agreement.

Type d'informations de prise en charge du partage d'IPD

  • ANALYTIC_CODE

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Non

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner